3D Global Biotech Past Earnings Performance
Past criteria checks 0/6
3D Global Biotech's earnings have been declining at an average annual rate of -4.7%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 50.8% per year.
Key information
-4.7%
Earnings growth rate
-2.6%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 50.8% |
| Return on equity | -6.4% |
| Net Margin | -53.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How 3D Global Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 55 | -29 | 31 | 39 |
| 31 Mar 24 | 38 | -44 | 30 | 39 |
| 31 Dec 23 | 21 | -58 | 30 | 39 |
| 30 Sep 23 | 19 | -61 | 29 | 39 |
| 30 Jun 23 | 16 | -65 | 28 | 40 |
| 31 Mar 23 | 15 | -66 | 29 | 40 |
| 31 Dec 22 | 14 | -67 | 30 | 39 |
| 30 Sep 22 | 12 | -67 | 30 | 39 |
| 30 Jun 22 | 10 | -67 | 31 | 38 |
| 31 Mar 22 | 10 | -63 | 29 | 38 |
| 31 Dec 21 | 11 | -60 | 26 | 38 |
| 30 Sep 21 | 13 | -54 | 24 | 37 |
| 30 Jun 21 | 15 | -49 | 22 | 37 |
| 31 Mar 21 | 14 | -48 | 21 | 36 |
| 31 Dec 20 | 13 | -48 | 20 | 36 |
| 30 Sep 20 | 13 | -47 | 22 | 27 |
| 30 Jun 20 | 14 | -47 | 24 | 17 |
| 31 Mar 20 | 16 | -41 | 27 | 9 |
| 31 Dec 19 | 18 | -36 | 30 | 0 |
| 31 Dec 18 | 12 | -40 | 38 | 0 |
| 31 Dec 17 | 9 | -36 | 40 | 0 |
Quality Earnings: 6808 is currently unprofitable.
Growing Profit Margin: 6808 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6808 is unprofitable, and losses have increased over the past 5 years at a rate of 4.7% per year.
Accelerating Growth: Unable to compare 6808's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6808 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (33.2%).
Return on Equity
High ROE: 6808 has a negative Return on Equity (-6.43%), as it is currently unprofitable.